Revenue declined 5.6% year-over-year due to lower lenalidomide sales and semaglutide API issues, but base business delivered double-digit growth across geographies. EBITDA margin was 12.5%, with guidance maintained near 20% as semaglutide supply is expected to resume in November. Strong growth in India and emerging markets offset U.S. generics headwinds.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.